Related Experiment Video

Updated: May 14, 2026

Quantitative 3D In Silico Modeling (q3DISM) of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
09:33

Quantitative 3D In Silico Modeling (q3DISM) of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease

Published on: December 26, 2016

Microglial chemotactic signaling factors in Alzheimer's disease

James G McLarnon1

  • 1Department of Anesthesiology, Pharmacology and Therapeutics, Faculty of Medicine, The University of British Columbia 2176 Health Sciences Mall, Vancouver, BC, Canada V6T 1Z3.

American Journal of Neurodegenerative Disease
|February 6, 2013
PubMed

Insights

Amyloid beta deposits trigger microglia migration in Alzheimer's disease (AD) brains. Targeting these chemotactic factors may reduce neuroinflammation and protect the brain.

Area of Science:

  • Neuroscience
  • Immunology
  • Cell Biology

Background:

  • Amyloid beta (Aβ) deposits in Alzheimer's disease (AD) induce microglial cell migration.
  • This chemotactic response is crucial for localizing microglia near Aβ for activation and immune response.
  • Microglial activation contributes to neuroinflammation in AD.

Purpose of the Study:

  • To review chemotactic factors involved in microglial migration towards Aβ deposits.
  • To explore the role of specific chemokines like MCP-1, MIP-1α, IL-8, VEGF, and fractalkine.
  • To consider the potential of targeting microglial chemotaxis for AD therapeutics.

Main Methods:

  • Literature review of studies on microglial chemotaxis in AD.
  • Summary of research on identified chemotactic factors and their receptors.
  • Discussion of potential therapeutic strategies targeting chemotaxis.

Main Results:

  • Key chemotactic factors identified include MCP-1, MIP-1α, IL-8, VEGF, and fractalkine.
  • Microglia accumulate at Aβ deposits, contributing to neuroinflammation.
  • MCP-1 may also influence neural progenitor cell chemotaxis.

Conclusions:

  • Multiple chemotactic factors mediate microglial responses to Aβ in AD.
  • Pharmacological modulation of microglial chemotaxis is a promising therapeutic avenue.
  • Targeting chemotaxis could inhibit neuroinflammation and promote neuroprotection in AD models.
Keywords:
AD animal models.Alzheimer’s disease (AD)Chemotactic factorsinflammatory responsesmicroglial chemotaxis

More Related Videos

Microglia as a Surrogate Biosensor to Determine Nanoparticle Neurotoxicity08:37

Microglia as a Surrogate Biosensor to Determine Nanoparticle Neurotoxicity

Published on: October 25, 2016

Immunofluorescence Staining Using IBA1 and TMEM119 for Microglial Density, Morphology and Peripheral Myeloid Cell Infiltration Analysis in Mouse Brain10:40

Immunofluorescence Staining Using IBA1 and TMEM119 for Microglial Density, Morphology and Peripheral Myeloid Cell Infiltration Analysis in Mouse Brain

Published on: October 27, 2019

Related Concept Videos

Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...